Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.
Alessio CortelliniMarco TucciVincenzo AdamoLuigia Stefania StucciAlessandro RussoEnrica Teresa TandaFrancesco SpagnoloFrancesca RastelliRenato BisonniDaniele SantiniMarco RussanoCecilia AnesiRaffaele GiustiMarco FilettiPaolo MarchettiAndrea BotticelliAlain GelibterMario Alberto OcchipintiRiccardo MarconciniMaria Giuseppa VitaleLinda NicolardiRita ChiariClaudia BareggiOlga NigroAlessandro TuziMichele De TursiNicola PetragnaniLaura PalaSergio BracardaSerena MacriniAlessandro InnoFederica ZorattoEnzo VeltriBarbara Di CoccoDomenico MallardoMaria Grazia VitaleDavid James PinatoGiampiero PorzioCorrado FicorellaPaolo Antonio AsciertoPublished in: Journal for immunotherapy of cancer (2021)
We confirmed the association between baseline steroids administered for cancer-related indication, systemic antibiotics, PPIs and worse clinical outcomes with PD-1/PD-L1 checkpoint inhibitors, which can be assumed to have immune-modulating detrimental effects.